Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children

The peak season of respiratory syncytial virus (RSV) infections in warmer climates may extend beyond the typical five-month RSV season of temperate regions. This study aimed to assess the safety, immunogenicity, and pharmacokinetics of an extended seven-dose regimen of palivizumab in children at high risk for serious infection by the RSV.